Zilver PTX is First Drug-Eluting Peripheral Stent

Cook Medical’s Zilver PTX introduced two stent sizes in the United States

 

November 15, 2012
Cook, Zilver PTX, stent, expanding, delivery sheath
The Cook Zilver PTX stent expanding from its delivery sheath.

Cook Medical’s Zilver PTX drug-eluting peripheral stent is the first device of its kind on several fronts to go before FDA review. It is the first drug-eluting stent (DES) for peripheral leg vessels, the first self-expanding DES and the first DES that does not use a polymer to load and elute its drug.

The Zilver PTX Drug-Eluting Stent is intended to treat peripheral arterial disease (PAD) in the superficial femoral artery (SFA). The stent is seen by many experts as a major step forward in treatment options for patients with peripheral artery disease (PAD) in the SFA. Occlusions in the SFA are difficult to treat and frequently re-occlude.

Zilver PTX is made of nitinol, a shape memory metal alloy that will spring back into its original shape under axial, torsional and bending flexibility. Self-expanding stents are used in the SFA because of the need to torque and compress with the vessel.

The addition of the anti-tissue proliferation drug paclitaxel on the Zilver stent has shown promising results in clinical trials in lowering the usually high restenosis rates of SFA lesions.

Polymers used to load drugs and control drug elution on DES have been implicated as the culprit in late-stent thrombosis sometimes seen in coronary stents. Vendors have been researching ways to eliminate polymers, allowing DES to become a bare metal stent following full drug elution into the vessel wall. The Zilver PTX would be the first DES in the United States not to use polymer, which is seen by many interventional experts as the way of the future.

In order to supply as many physicians as possible with this new technology, Cook is making Zilver PTX available initially in 80 mm lengths in 6 mm and 7 mm diameters. The products indications for use also allow two Zilver PTX 80 mm stents to be overlapped to treat longer lesions up to 140 mm. The FDA approval also includes 40 mm and 60 mm lengths, which will be introduced to the U.S. early in 2013. Cook expects to receive regulatory approval for 120 mm length stents in both diameters next year.

The U.S. Food and Drug Administration (FDA) granted market clearance for for the stent in November 2012. The stent gained European CE mark approval in 2009.  The device is being introduced to the U.S. market in a five-step process designed to make this technology available to as many patients as possible initially.

For more information: www.cookmedical.com

 

The content of this field is kept private and will not be shown publicly.
Type the characters you see in this picture. (verify using audio)
Type the characters you see in the picture above; if you can't read them, submit the form and a new image will be generated. Not case sensitive.